Ontology highlight
ABSTRACT:
SUBMITTER: Masarova L
PROVIDER: S-EPMC6265645 | biostudies-literature | 2018 Oct
REPOSITORIES: biostudies-literature
Masarova Lucia L Verstovsek Srdan S Hidalgo-Lopez Juliana E JE Pemmaraju Naveen N Bose Prithviraj P Estrov Zeev Z Jabbour Elias J EJ Ravandi-Kashani Farhad F Takahashi Koichi K Cortes Jorge E JE Ning Jing J Ohanian Maro M Alvarado Yesid Y Zhou Lingsha L Pierce Sherry S Gergis Romany R Patel Keyur P KP Luthra Rajyalakshmi R Kadia Tapan M TM DiNardo Courtney D CD Borthakur Gautam G Bhalla Kapil K Garcia-Manero Guillermo G Bueso-Ramos Carlos E CE Kantarjian Hagop M HM Daver Naval N
Blood 20180905 16
Ruxolitinib (RUX)-based combinations may provide benefit for patients with myelofibrosis (MF). In this open-label, nonrandomized, prospective phase 2 study, patients with MF initially received RUX twice per day continuously in 28-day cycles for the first 3 cycles. Azacitidine (AZA) 25 mg/m<sup>2</sup> (days 1-5) was added starting with cycle 4 and could be subsequently increased to 75 mg/m<sup>2</sup> (days 1-5). Forty-six patients were enrolled with a median follow-up of 28 months (range, 4-50+ ...[more]